Vinmec performs its first total femoral replacement for world's youngest cancer patient
HANOI, VIETNAM - Media OutReach Newswire - 11 June 2025 - Vinmec Healthcare System has successfully performed a Total Femoral Replacement (TFR) surgery using personalized 3D printing materials for the world's youngest cancer patient. It is also the first biomedical product designed and produced entirely in Vietnam, marking a major milestone in the country's advancement in precision medicine.
Refusing to Surrender to Fate
In October 2022, after a minor fall, Tran Minh Duc (a boy from Ho Chi Minh City) hurt his left thigh. Believing it to be just a simple injury, his family was shocked to hear the bad news from the doctor: The boy was diagnosed with osteosarcoma - a malignant bone cancer with a tumor that had invaded his entire femur. It is typically seen in adolescents, but rare and haphazard in younger children.
Given the severe prognosis, most medical facilities recommended amputation to ensure his survival or bone grafting (a conventional method). Both methods carry a high risk of rejection and infection, especially for younger children in the development stage.
The flash of hope appeared when she met Prof. Dr. Tran Trung Dung - Director of the Orthopedic Council, Vinmec Healthcare System. An unprecedented approach was proposed to apply to such a young patient: replacing the entire femur with personalized 3D-printed materials that are produced in Vietnam.
A 'Legendary' Surgery with Vietnamese Technologies
According to Prof. Dr. Tran Trung Dung, the entire femur of Duc has been invaded by the tumor. To ensure his life, Duc's leg had to be amputated. However, different types of artificial joints available on the market are not compatible with young bodies.
After various interdisciplinary case conferences including Orthopedics, Oncology, Diagnostic Imaging, Pathology, Clinical Pharmacy, etc., the Vinmec experts reached a consensus on the optimal approach - a two-phase surgery. Phase 1 (January 2024): Removing the tumor and temporarily grafting a cement bone. Phase 2 (May 2025): Replacing the entire femur with a 'customized' bone made of 3D-printed metal.
On January 29, 2024, Duc underwent his first surgery - removing the entire tumor and temporarily grafting a cement bone. In May 2025 when his conditions had stabilized, Duc's entire femur was replaced with a 'customized' bone made of 3D-printed metal. For the first time, 3D printing was applied to the youngest patient in the world with the collaboration between Vinmec medical professionals and VinUni's engineers. The bone's design is modular, enabling future extensions based on the child's physical development.
According to MSc. Dr. Tran Duc Thanh, who was directly engaged in the surgery: 'We contacted foreign manufacturers but there was no suitable design. Self-manufacturing the equipment allows us to be proactive in treatment, it also paves the way for a new direction for Vietnamese medicine.'
Prof. Dr. Tran Trung Dung added: 'The 4-hour surgery was a success. Duc recovered quickly without any complications, now he is able to walk with the support of physical therapy. The surgery represented a breakthrough in complex techniques and the evidence for sound collaboration in the multidisciplinary medical team. Both the life and limb of the child were kept intact.'
Vinmec - Pioneering in Vietnam's Personalized Precision Medicine
Once at risk of amputation and life-long dependence, Minh Duc is now able to walk on his own feet, supported by physical therapy without any complications of infection or transplant rejection. Every step Duc takes is a testament to precision medicine, advanced technologies, and the unwavering love of his mother.
'When my son stood up, I was trembling with joy. He has been unable to walk for nearly two years. Now he did it. I just hope that he will be capable of riding a bike and playing football like his peers...' - Ms. Hoang said in tears.
Prof. Dr. Tran Trung Dung also shared his emotions: 'We believe that modern medicine and compassion should go side by side. Duc is not just a special patient, his case represents a story of determination, maternal love, and the faith that the impossible can become possible if we never give up.'
Vinmec is the first Vietnamese healthcare system that applies personalized 3D printing in the treatment of musculoskeletal conditions. Instead of using standardized equipment, Vinmec uses CT and MRI data in the design of artificial joints and bones tailored to each patient to optimize motor functions, enhance precision, and reduce the recovery period.
To date, Vinmec has achieved successes in many difficult and rare cases, e.g. liver transplantation for an 8-month-old patient from a brain-dead donor, the first in Southeast Asia to reproduce 3D-printed titanium chest wall, and the first in the world to replace the pelvis and femur at the same time with 3D-printed bones.
With its series of breakthroughs and pioneering achievements in high-tech healthcare and precision medicine, Vinmec further affirms the aspiration to elevate the position of Vietnam in the global medical field.
Vinmec - A Place of Healing and Reimagining the Future.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
3 days ago
- The Sun
Rethinking Obesity: Novo Nordisk's Latest
SINGAPORE - Media OutReach Newswire - 27 June 2025 - Imagine a chronic disease affecting more than 600,000 people 1-3 in Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This is the reality of obesity today. For many, outdated perceptions and delays in care have created barriers to support and treatment. Today, a new initiative is calling for a shift — to change how we think, talk about, and respond to obesity, through a lens of science, empathy, and early intervention. Breaking the Myths: A Public Health Reframe 'Just eat less.' 'Try harder.' 'It's a lifestyle choice.' These are more than just phrases — they reflect a deeper misunderstanding of obesity. Today, a bold new initiative, seeks to challenge those misconceptions and open the door to a more compassionate, evidence-based conversation. 'Beyond the Scale' launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, but as a complex, chronic disease. The initiative invites the public to go beyond — beyond stigma, beyond myths, beyond labels — and recognise obesity for what science confirms it to be: a multifactorial health condition that deserves understanding, early intervention, and clinical care. Led by global healthcare company Novo Nordisk in collaboration with local healthcare professionals and patient advocates, 'Beyond the Scale' is a disease awareness initiative aimed at driving a shift in how individuals, communities, and healthcare providers approach obesity management. 'We believe it's time to shift from blame to understanding,' said General Manager, Mr Vincent Siow of Novo Nordisk Singapore. 'Obesity affects 1 out of 9 people in Singapore4, yet it's still too often seen as a matter of willpower. The reality is that obesity is a complex, chronic disease driven by biology, environment, and unequal access to care.1,5 It's time we treat it with the seriousness it deserves — and we are proud to lead that conversation and drive meaningful change through the 'Beyond the Scale' initiative. Why This Matters Now The 2021–2022 National Population Health Survey reveals the highest obesity rate (15%) among adults aged 40 to 49, while 43.3% of residents aged 18 to 74 had abdominal obesity, which increases with age and peaks between 50 to 74 years.6 This is compounded by the fact that perceptions persist about obesity being a personal failing, discouraging individuals from seeking help, delaying diagnosis, and compounding the health burden on families and the healthcare system. Obesity significantly increases the risk of cardiovascular disease (CVD), type 2 diabetes, and chronic kidney disease (CKD)7, all of which already place a growing strain on Singapore's healthcare infrastructure. The economic impact is substantial: in 2019, metabolic-risk related diseases, including obesity, diabetes, hypertension, CKD, and cardiovascular conditions, cost Singapore S$2.20 billion.8 Of this, S$642 million were healthcare expenditures8, and excess weight alone accounted for an estimated S$261 million in annual medical and absenteeism costs.9 Without decisive public health action, these obesity-related comorbidities are poised to escalate into a major societal and economic burden. 'This is not just a personal issue — it's a public health priority,' said Dr Ben Ng, Arden Diabetes & Endocrine Clinic. 'We know obesity changes how the body regulates appetite, energy storage, and metabolism. It's a disease, not a choice. Science supports this — and our response should reflect it.' The Science Behind the Message Obesity is not simply about calories in and out. Research confirms it involves neuroendocrine (hormonal), genetic, and psychosocial factors, making it both preventable and treatable10 . Studies show that in Singapore, weight stigma is often driven by the belief that obesity is a personal failing, lack of willpower, or lifestyle choice leading to delayed treatment, reduced care-seeking, and poorer health outcomes, particularly in managing chronic conditions such as cardiovascular and kidney disease.11 Beyond Labels, Toward Lasting Change 'Beyond the Scale' is more than a slogan — it is a call to treat obesity as the complex, chronic disease that it is. To move away from blame, appearance-based judgments, and oversimplified narratives, toward empathy, science, and sustained health. It is an urgent appeal to rethink, retrain, and rehumanise the way we support individuals living with obesity. 'The earlier we intervene, the better the outcomes,' said Dr. Ng. 'Obesity is not a character flaw. It's a disease. And it's time we responded with the same respect, science, and care we give every other chronic condition.' 'Beyond the Scale' aims to: Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage timely, evidence-based conversations with healthcare professionals. Promote empathy and science within the medical community. Support patients with tools to take charge of their health. Singaporeans can participate by: Visiting [ for factual resources, use a BMI measurement tool, and locate a nearest weight management healthcare professional. Starting honest conversations with GPs, nurses, and pharmacists. Sharing content to help dismantle myths and support loved ones on their health journeys. 1. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. 2. World Obesity. Retrieved from 3. World Obesity. Retrieved from 4. Lee, Y. V., & Tan, N. C. (2014). Obesity in Singapore: An update. The Singapore Family Physician, 40(2), 11–16. 5. World Health Organization. (2024). Obesity and As accessed on 22nd May 2025. 6. Ministry of Health, Singapore. (2022). National Population Health Survey 2022 Report. 7. Cohen JB, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. Curr Hypertens Rep. 2015 May;17(5):34. doi: 10.1007/s11906-015-0544-2. PMID: 25833456; PMCID: PMC4427189. 8. Tan, V., Lim, J., Akksilp, K. et al. The societal cost of modifiable risk factors in Singapore. BMC Public Health 23, 1285 (2023). (2.2 Billion) 9. Junxing C, Huynh VA, Lamoureux E, Tham KW, Finkelstein EA. Economic burden of excess weight among older adults in Singapore: a cross-sectional study. BMJ Open. 2022 Sep 16;12(9):e064357. doi: 10.1136/bmjopen-2022-064357. PMID: 36113947; PMCID: PMC9486358. 10. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290. 11. Goff AJ, Lee Y, Tham KW. Weight bias and stigma in healthcare professionals: a narrative review with a Singapore lens. Singapore Med J. 2023 Mar;64(3):155-162. doi: 10.4103/ PMID: 36876621; PMCID: PMC10071861. Hashtag: #NovoNordisk
The Sun
22-06-2025
- The Sun
Key Findings from the 'Hong Kong Vitiligo Patients and Caregivers Survey' Released for 'World Vitiligo Day'
Patients Demonstrate Significant Knowledge Gaps in Treatment Options, Leading to Lost Hope and Treatment Discontinuation Over 70% of Vitiligo Patients Desire Skin Repigmentation; New Topical Therapy Introduced in Hong Kong Shows Encouraging Results HONG KONG SAR - Media OutReach Newswire - 22 June 2025 - In observance of World Vitiligo Day (June 25), Hong Kong Vitiligo Support Group has released findings from its latest 'Hong Kong Vitiligo Patients and Caregivers Survey.' The study reveals critical gaps in treatment knowledge, with over 80% of respondents demonstrating limited understanding of available therapies and their efficacy. More than 70% of patients hoped therapy could partially or fully restore their original skin pigmentation, yet many reported disappointing outcomes with existing treatments, leading to loss of confidence and treatment discontinuation. Dr. Chan Yung, a specialist in dermatology, noted that with advancing insights into vitiligo pathogenesis, novel therapy has recently been introduced in Hong Kong. Clinical studies confirm its repigmentation potential, encouraging patients to consult specialists for personalized treatment plans. In Hong Kong, vitiligo affects approximately 1% of the population, with an estimated 70,000 individuals living with the condition. In May 2025, Hong Kong Vitiligo Support Group successfully surveyed 61 patients or their primary caregivers to identify key challenges in disease management. Key findings as follows: 1. Critical Knowledge Deficits in Treatment Understanding · 80% lack understanding of treatment options · 78% unfamiliar with medication efficacy · 84% uncertain about which specialist to consult 2. Disparity Between Treatment Expectations and Outcomes · 74% of respondents expressed a desire for full or partial skin repigmentation, yet among the 48 treated patients, none achieved complete repigmentation, and only 8% reported partial improvement · 67% perceived treatments as completely ineffective 3. Treatment Discontinuation Due to Lost Confidence · 43% are not receiving any active treatment at present · Barriers included: high private healthcare costs and long public-sector wait times (95%), and perceived futility of therapy (75%) Vitiligo is classified as segmental (SV) or non-segmental (NSV), with 90% of cases being NSV—a subtype with higher progression risk and greater therapeutic difficulty. Traditional options (e.g., topical corticosteroids, topical calcineurin inhibitors, phototherapy) often yield variable results, with limitations such as: · Corticosteroids: Risk of skin atrophy, telangiectasia; unsuitable for long-term use · Phototherapy: Requires 3–6 months (or longer) of 2–3 weekly sessions, with potential sunburn and skin cancer risks · Non-steroidal topicals: Often only slow progression rather than induce repigmentation Over 70% of Vitiligo Patients Seek Skin Repigmentation - New Topical Treatment Introduced in Hong Kong Offers Hope Dr. Chan Yung stated that targeted therapies like topical JAK inhibitors represent a breakthrough in vitiligo treatment. 'Topical JAK inhibitors are non-steroidal medications with demonstrated efficacy and safety profiles, making them a viable long-term treatment option for patients,' he explained. While the exact etiology of vitiligo remains unclear, current evidence suggests autoimmune-mediated attack on melanocytes plays a key pathogenic role, resulting in depigmented lesions. Non-steroidal Topical JAK inhibitors work by modulating the aberrant immune signaling responsible for melanocyte attack, enabling gradual repigmentation of affected areas. Ruxolitinib cream, the first FDA-approved non-steroidal topical JAK inhibitor for localized treatment of non-segmental vitiligo in patients aged 12 years and above, has recently become available in Hong Kong. Clinical trials show: · Approximately 30% of patients achieved ≥75% improvement in Facial Vitiligo Area Scoring Index (F-VASI) after 24 weeks of treatment; · 50% of patients showed ≥50% improvement; · Extension to 52 weeks of treatment resulted in >50% of patients attaining ≥75% improvement⁷ Ms. Amy Wong, a Registered Social Worker at Hong Kong Vitiligo Support Group noted that many vitiligo patients and caregivers seeking assistance express confusion about treatment options and medication efficacy. 'Many patients spend over a year just obtaining a definitive diagnosis,' she explained. 'In their search for solutions, patients often invest substantial resources in various cosmetic packages and alternative therapies, only to experience significant discrepancies between desired and actual outcomes. This frequently leads to disillusionment, loss of hope for effective treatment, and even emotional distress.' 'However,' Ms. Wong emphasized, 'with medical advancements, vitiligo is no longer considered untreatable. Repigmentation is now achievable, and we strongly encourage patients to seek professional medical consultation at the earliest opportunity.' Conclusion and Recommendations The survey reveals significant gaps in patients' understanding of vitiligo treatments and their mechanisms, leaving many uncertain about where to begin treatment. Over 80% of respondents expressed desire for patient support in medication access and resource referrals. Accordingly, Dr. Chan Yung and Ms. Amy Wong, propose the following recommendations: 1. Public Education Seminars Conduct lectures and workshops to help patients and caregivers understand that vitiligo requires long-term management, with visible results often taking extended periods to manifest. These initiatives should also educate participants about various treatment modalities, particularly newly available options like non-steroidal topical JAK inhibitors, enabling informed discussions with healthcare providers about appropriate treatment plans. 2. Medication Support and Resource Referral Services Given that vitiligo necessitates prolonged treatment, and considering that many patients find private care cost-prohibitive while public service wait times are excessively long, we recommend establishing medication support and resource referral services to facilitate timely access to proper treatment. Hong Kong Vitiligo Support Group is currently implementing a 'Vitiligo Patient Support Program,' offering free psychological counseling, medication assistance, and resource referral services. Interested individuals may contact Hong Kong Vitiligo Support Group for details. Case Study Mr. Chan (pseudonym), 58, first developed symptoms thirty years ago with a small depigmented spot on his neck that subsequently spread to his neck, waist, wrists, and thighs. At diagnosis, his physician prescribed topical corticosteroids but stated vitiligo was essentially 'incurable.' Mr. Chan subsequently pursued numerous alternative treatments including UV light therapy, traditional Chinese medicine, electroacupuncture, topical shampoo applications, and cosmetic packages - exhausting savings and liquidating his stocks - all without achieving satisfactory repigmentation. After years of unsuccessful treatment attempts, he discontinued treatment until being referred to the Hong Kong Vitiligo Support Group. Through their seminars and 'Vitiligo Patient Support Program', he learned about modern treatment advances and, with medication assistance, has begun new therapy with renewed hope for repigmentation. 'My greatest wish is to wear crew-neck shirts again,' Mr. Chan shared. 'Since developing vitiligo, I've only worn high-collared shirts to conceal neck patches and haven't gone swimming in thirty years.' He looks forward to regaining sartorial freedom following successful repigmentation.
The Sun
20-06-2025
- The Sun
Prudential plc CEO Expresses Strategic Commitment to India in Meeting with Union Finance Minister Nirmala Sitharaman
NEW DELHI, INDIA - Media OutReach Newswire - 20 June 2025 - Prudential plc ('Prudential') Chief Executive Officer, Anil Wadhwani, met yesterday with Smt. Nirmala Sitharaman, Union Minister for Finance and Corporate Affairs, Government of India, emphasising India's strategic importance to the UK FTSE100 insurer and asset manager operating across Asia and Africa. Prudential provides life insurance solutions in India through ICICI Prudential Life Insurance Company Limited, a preeminent life insurer and the first private insurance company listed in India. It also has a market-leading asset management presence via a separate joint venture with ICICI Bank, ICICI Prudential Asset Management Co. Ltd. Earlier this year, Prudential announced plans to establish a standalone health insurance joint venture with Vama Sundari Investments (Delhi) Private Limited, a promoter company of the HCL Group. During the meeting, Mr. Anil Wadhwani remarked: 'We are deeply proud of our heritage in India, which began with our first branch in Kolkata in 1923. India is a core strategic market for Prudential. As the country advances towards its vision of 'Insurance for All' and continues to address the challenge of underinsurance, we see significant opportunities to bring our global expertise in protection, savings, and health solutions to serve the evolving needs of Indian consumers. Our long-standing connection with India, including our sponsorship of the historic 1983 Cricket World Cup, India's first World Cup victory, reflects our commitment to its growth and aspirations.' Highlighting health as a shared strategic priority, Mr. Wadhwani conveyed the company's commitment to leveraging its global expertise and technology to help Indian consumers access affordable and quality healthcare coverage. This aligns with the Government of India's vision of 'Insurance for All by 2047'. India is not only a key strategic insurance market but also an incredible source of talent. Prudential recently launched a Global Capability Centre in Bengaluru. This strategic hub serves as a global centre for technology, AI, data analytics, cybersecurity, and innovation. Concluding the meeting, Mr. Wadhwani said: 'India's economic progress over the past decade has been remarkable. With sustained capital investment in infrastructure and proactive government economic measures to stimulate growth, we remain excited about India's long term growth prospects. We look forward to continuing our constructive collaboration with the Indian government to support its development goals and to build enduring insurance and technology businesses.' During the visit, Mr. Wadhwani also met with senior officials from the Department for Promotion of Industry and Internal Trade (DPIIT) and the Prime Minister's Office.
